Cell-specific mechanism-based gene therapy approach to treat retinitis pigmentosa

September 30, 2011

In a paper published in the October 2011 issue of Experimental Biology and Medicine, a team of researchers at Columbia University Medical Center led by Stephen Tsang, MD, Ph.D have achieved temporary functional preservation of photoreceptors in a mouse model for retinitis pigmentosa (RP) using novel bipartite gene therapy.

RP is a heterogeneous disorder characterized by of rod photoreceptors (which mediate night vision) causing night blindness and eventually total blindness. About 36,000 cases of simplex and familial RP worldwide are caused by mutant phosphodiesterase (PDE6). Says Dr. Tsang,

"Victor McKusick's Mendelian Inheritance in Man catalog has approximately 4,000 genetic disease entries, but only 4 of these are already curable by gene-therapy approaches. This bipartite vector, which allows cell-specific delivery of both the normal gene and shRNA to knockdown other genes in the pathway, represents a strategy that may help cure many more retinal degenerations. Degeneration of rod photoreceptors also affects approximately 9 million Americans with age-related . Strategies to save photoreceptors in mouse models of RP may be applicable to that disease as well."

In spite of this high prevalence, the interplay between defective PDE metabolism and RP remains poorly understood. In several mouse models for RP, defects in the PDE6B enzyme result in increased levels of the signaling molecules cGMP (mediated by GUCY2E cyclase) and Ca2+ (mediated by the CNGA1 channel).

Several aspects of the EBM report are innovative. It not only tackles the lack of functional PDE6β (by augmenting function with conventional gene replacement), but simultaneously counteracts the central biochemical impact of that lost function by decreasing abnormally accumulated cGMP and Ca2+. Furthermore, they used a tissue-specific promoter to achieve cell-specific expression of the transduced genes, which is unusual for shRNA delivery.

The researchers at Columbia developed three different lentiviral vectors, each of them designed to deliver wild-type Pde6b cDNA and one of two shRNAs. One vector delivered the cDNA and GUCY2E shRNA to reduce cGMP levels; another vector delivered the wild-type cDNA and CNGA1 shRNA to reduce Ca2+ levels; the third delivered the cDNA and the Gucy2e shRNA with a tissue-specific promoter. The bipartite approach was conceived as a way to improve therapeutic efficacy over that of a single-therapy approach, which was tested in an earlier project from Dr. Tsang's lab. While the current project did not show improvement over their previous work, the researchers are optimistic that bipartite delivery may represent an important resource in future explorations of gene therapy in the eye and other tissues types.

Typical existing shRNA vector systems use the RNA polymerase III promoter, which is expressed in essentially all cell types, to drive expression of the transduced gene. However, expression of shRNA targeting GUCY2E in cone photoreceptors, which mediates color vision, would have unwanted and deleterious effects on vision. To achieve rod-specific expression of the shRNA, the researchers in this work embedded Gucy2e shRNA into the Pol II transcription unit of pre-miR34, which is expressed solely in rods. Similar methods can be used to target different tissues, so this method may have wide applicability.

The testing of therapeutic approaches in Pde6bH620Q mice should facilitate pre-clinical therapeutic evaluation of retinitis pigmentosa. Lessons learned from the proposed studies will eventually be translated into strategies for treatment trials in larger animal models of PDE6β deficiency, such as Irish Setter dogs, before seeing application in human therapeutics.

Dr. Steve Goodman, Editor-in-Chief of said, "Researchers at Columbia University Medical Center led by Stephen Tsang, MD, Ph.D have used a unique gene therapy approach to preserve photoreceptors and prolong functional vision in a of retinitis pigmentosa (RP). There work offers the promise of a future cure for RP".

Explore further: Study: Antioxidants may slow vision loss

Related Stories

Study: Antioxidants may slow vision loss

July 19, 2006

U.S. scientists say they've blocked the advance of retinal degeneration in mice with a form of retinitis pigmentosa by treating them with antioxidants.

Blind mice shed light on human sight loss

November 22, 2007

Mutant mice could provide genetic clues to understanding incurable human sight loss resulting from retinal degeneration. Research published in the online open access journal Genome Biology uncovers a role for microRNA in ...

Cats' eye diseases genetically linked to diseases in humans

March 4, 2009

About one in 3,500 people are affected with retinitis pigmentosa (RP), a disease of the retina's visual cells that eventually leads to blindness. Now, a University of Missouri researcher has identified a genetic link between ...

Developing gene therapy to fight blindness

July 29, 2009

An international team of scientists and clinicians from the United States and Saudi Arabia are working to develop gene therapy for treating a rare, hereditary retinal disease. The therapy has been shown to restore lost vision ...

Modeling retinitis pigmentosa with iPS cells

March 9, 2011

Retinitis pigmentosa (RP) is a cluster of genetically determined eye disorders that cause visual defects such as night blindness and narrowing of the field of vision, due to progressive loss of rod photoreceptors. As many ...

Recommended for you

Basic research fuels advanced discovery

August 26, 2016

Clinical trials and translational medicine have certainly given people hope and rapid pathways to cures for some of mankind's most troublesome diseases, but now is not the time to overlook the power of basic research, says ...

New method creates endless supply of kidney precursor cells

August 25, 2016

Salk Institute scientists have discovered the holy grail of endless youthfulness—at least when it comes to one type of human kidney precursor cell. Previous attempts to maintain cultures of the so-called nephron progenitor ...

New avenue for understanding cause of common diseases

August 25, 2016

A ground-breaking Auckland study could lead to discoveries about many common diseases such as diabetes, cancer and dementia. The new finding could also illuminate the broader role of the enigmatic mitochondria in human development.

Strict diet combats rare progeria aging disorders

August 25, 2016

Mice with a severe aging disease live three times longer if they eat thirty percent less. Moreover, they age much healthier than mice that eat as much as they want. These are findings of a joint study being published today ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.